home / stock / lgvn / lgvn news

LGVN News and Press, Longeveron Inc. From 09/05/23

Stock Information
Company Name: Longeveron Inc.
Stock Symbol: LGVN
Market: NASDAQ
Website: longeveron.com
Menu
LGVN LGVN Quote LGVN Short LGVN News LGVN Articles LGVN Message Board
Get LGVN Alerts

News, Short Squeeze, Breakout and More Instantly...
LGVN - InvestorNewsBreaks - Longeveron Inc. (NASDAQ: LGVN) to Present at Upcoming H.C. Wainwright Global Investment Conference

Longeveron (NASDAQ: LGVN, LGVNR) , a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty, today announced t...
LGVN - Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference

MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left h...

LGVN - MVST, GDC and HYFM among mid-day movers

2023-08-31 12:41:47 ET Gainers: Acer Therapeutics ( ACER ) +133% . Prime Number Acquisition I Corp. ( NCNC ) +41% . Minim ( MINM ) +29% . Canopy Growth Corporation ( CGC ) +26% . Upland Software ( UPLD ) +23% . Hydrofarm Hold...

LGVN - Mesoblast, Longeveron, Lifecore Biomedical among healthcare movers

2023-08-31 10:00:40 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) Tech Ruled The First Half Of 2023, The Industry You Need To Watch In The Second Half XLV Vs. VHT: A Head-To-Head Healthcare ETF C...
LGVN - InvestorNewsBreaks - Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Participation at Upcoming National Investment Banking Association Conference

Longeveron (NASDAQ: LGVN; LGVNR) , a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and aging-related frailty, will be presentin...

LGVN - Longeveron to Participate in the 149th Annual National Investment Banking Association Conference

MIAMI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left he...

LGVN - Longeveron Rights Offering Subscription Period Begins

MIAMI, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left he...
LGVN - Longeveron Rights Offering Declared Effective and Calendar Finalized

MIAMI, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (...

LGVN - Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B(TM) on August 16, 2023

MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it will host a virtual KOL Event on August 16, 2023 at 10:00 AM ET. Click here...

LGVN - Longeveron announces pricing for rights offering

2023-08-14 15:44:10 ET More on Longeveron Longeveron Inc. ( LGVN ) Q2 2023 Earnings Call Transcript Longeveron spikes on long-term survival data for heart disease candidate Longeveron spikes after FDA’s Fast Track Designation for lead candidate For...
Previous 10 Next 10